Genérico Cyclophosphamide - Cytoxan
|
Farmacia Online de máxima seriedad, confianza y seguridad
Envíos discretos hasta su casa u oficina
|
|
|
Lista de categorías
AnalgésicosAntibióticosAntidepresivosAntiinflamatoriosDisfunción EréctilPérdida De PesoSalud Masculina
Debo excusarme - pensaba que ustedes querian engañarme. Pero la demora era causada por un error. Recibí el encargo el jueves 8 de junio, y el otro el sábado 10 de junio. ¡ Tardo casi un mes pero fue a causa de un error en los datos de envio! Muchas gracias. - Curt
Nuestra página de facturación está certificada por:
- Cyclophosphamide drug makes the bone marrow more tumor-friendly - News-Medical.net
Cyclophosphamide drug makes the bone marrow more tumor-friendlyNews-Medical.
- Docs Need Primer on Long-Term Effects of Chemotherapy - Family Practice News Digital Network
Family Practice News Digital NetworkDocs Need Primer on Long-Term Effects of ChemotherapyFamily Practice News Digital NetworkOnly 6% of primary care physicians were able to identify the main long-term effects (LEs) of doxorubicin (Adriamycin), paclitaxel (Taxol), oxaliplatin (Eloxatin), and cyclophosphamide (Cytoxan), compared with 65% of oncologists surveyed.
- Diffuse Large B-Cell Lymphoma: Current Treatment Approaches - Cancer Network
Diffuse Large B-Cell Lymphoma: Current Treatment ApproachesCancer NetworkWhile a series of trials support R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone, plus rituximab)-21 as the standard of care for all patients, DLBCL has substantial biological and clinical heterogeneity, leading to marked differences .
- Some Doctors Unaware of Long-Term Effects of Cancer Care - Cleveland News - Fox 8
Cleveland News - Fox 8Some Doctors Unaware of Long-Term Effects of Cancer CareCleveland News - Fox 8In the case of Cyclophosphamide, only 14% of primary care physicians knew women are likely to suffer premature menopause, compared to 71% of cancer specialists.
- First cycle G-CSF for high-risk chemotherapy: Of Course! - Clinical Oncology News
Clinical Oncology NewsFirst cycle G-CSF for high-risk chemotherapy: Of Course!Clinical Oncology NewsDawn Hershman, MD, of Columbia University in New York City, recently published an article in the Journal of Clinical Oncology noting the rapid uptake of dose-dense AC-Taxol (doxorubicin and cyclophosphamide followed by paclitaxel [ddAC-T]).
 |
Agregar a favoritos |
|---|
 |
Apuntarse a lista de correo |
|---|
Copyright © www.eurpharmacy.com. Todos los derechos reservados.